Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Recruiting

Phase 3

Pneumococcal VaccineStudy of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Sponsor:

Sanofi

Code:

NCT06824194

Conditions

Pneumococcal Immunization

Eligibility Criteria

Sex: All

Age: 42 - 70+

Healthy Volunteers: Accepted

Interventions

PCV21 vaccine

Prevnar 20 vaccine

M-M-R II vaccine

Rotarix

RotaTeq

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by Sanofi on 2025-05-23.